Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: Feasibility and long-term results from a phase II randomized trial

Kouloulias, V; Plataniotis, G; Kouvaris, J; Dardoufas, C; Gennatas, C; Uzunoglu, N; Papavasiliou, C; Vlahos, L

dc.contributor.author	Kouloulias, V	en
dc.contributor.author	Plataniotis, G	en
dc.contributor.author	Kouvaris, J	en
dc.contributor.author	Dardoufas, C	en
dc.contributor.author	Gennatas, C	en
dc.contributor.author	Uzunoglu, N	en
dc.contributor.author	Papavasiliou, C	en
dc.contributor.author	Vlahos, L	en
dc.date.accessioned	2014-03-01T01:21:59Z
dc.date.available	2014-03-01T01:21:59Z
dc.date.issued	2005	en
dc.identifier.issn	0277-3732	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/16424
dc.subject	5-fluoroucil and mitomycin	en
dc.subject	Anal cancer	en
dc.subject	Intracavitary hyperthermia	en
dc.subject	Radiotherapy	en
dc.subject	Randomized study	en
dc.subject.classification	Oncology	en
dc.subject.other	fluorouracil	en
dc.subject.other	mitomycin C	en
dc.subject.other	adult	en
dc.subject.other	aged	en
dc.subject.other	anus	en
dc.subject.other	anus cancer	en
dc.subject.other	anus sphincter	en
dc.subject.other	article	en
dc.subject.other	bladder disease	en
dc.subject.other	blood toxicity	en
dc.subject.other	clinical trial	en
dc.subject.other	colostomy	en
dc.subject.other	controlled clinical trial	en
dc.subject.other	controlled study	en
dc.subject.other	enteropathy	en
dc.subject.other	female	en
dc.subject.other	human	en
dc.subject.other	hyperthermic therapy	en
dc.subject.other	male	en
dc.subject.other	microwave irradiation	en
dc.subject.other	morbidity	en
dc.subject.other	radiation dose	en
dc.subject.other	randomized controlled trial	en
dc.subject.other	rectum	en
dc.subject.other	recurrent disease	en
dc.subject.other	skin toxicity	en
dc.subject.other	survival	en
dc.subject.other	Aged	en
dc.subject.other	Antineoplastic Combined Chemotherapy Protocols	en
dc.subject.other	Anus Neoplasms	en
dc.subject.other	Combined Modality Therapy	en
dc.subject.other	Diathermy	en
dc.subject.other	Dose Fractionation	en
dc.subject.other	Female	en
dc.subject.other	Fluorouracil	en
dc.subject.other	Humans	en
dc.subject.other	Male	en
dc.subject.other	Middle Aged	en
dc.subject.other	Mitomycin	en
dc.subject.other	Survival Analysis	en
dc.title	Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: Feasibility and long-term results from a phase II randomized trial	en
heal.type	journalArticle	en
heal.identifier.primary	10.1097/01.coc.0000139939.60056.42	en
heal.identifier.secondary	http://dx.doi.org/10.1097/01.coc.0000139939.60056.42	en
heal.language	English	en
heal.publicationDate	2005	en
heal.abstract	Purpose: The purpose of this study was to investigate in a randomized way the clinical benefit of addition of intracavitary hyperthermia (ICHT) to a conventional chemoradiotherapy schedule in patients with T2-T3N0M0 anal cancer. Methods and Materials: Patients were randomly assigned to undergo chemotherapy with 5-fluorouracil (5-FU) and mitomycin-C combined with radiotherapy with (arm A: 24 patients) or without ICHT (arm 13: 25 patients). A microwave applicator operating at 43 3 MHz inserted into the anal-rectal cavity was used for ICHT. Patients in both aims received 1000 mg/m(2) per day of 5-FU on days 1-4 and days 28-31 plus 15 mg/m(2) mitomycin-C on day 1. Radiotherapy was administered with a dose of 41.4 Gy (1.8 Gy per fraction) plus a booster dose of 14 Gy (2 Gy per fraction). Results: One patient from group A developed severe mucositis, whereas no severe morbidity was noted in the rest of the patients in both groups. The incidence of lower-intestine acute reactions was higher in the ICHT arm. After a 5-year follow up in the hyperthermia arm, 23 of 24 patients (95.8%) preserved their anorectal function and avoided permanent colostomy, whereas in the second arm, 17 of 25 (68.0%) had sphincter preservation. Local recurrence-free survival time was significantly higher in the ICHT arm (P = 0.0107, log rank test), whereas no significant difference in overall survival was note I. Conclusion: The addition of ICHT to the chemoradiotherapy schedule of anal cancer seems to offer a new effective and safe therapeutic modality. The preservation of anorectal function seems to be the significant clinical benefit of adjuvant ICHT.	en
heal.publisher	LIPPINCOTT WILLIAMS & WILKINS	en
heal.journalName	American Journal of Clinical Oncology: Cancer Clinical Trials	en
dc.identifier.doi	10.1097/01.coc.0000139939.60056.42	en
dc.identifier.isi	ISI:000226851500016	en
dc.identifier.volume	28	en
dc.identifier.issue	1	en
dc.identifier.spage	91	en
dc.identifier.epage	99	en